QUEBEC CITY, Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris
Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today
that the remaining 11,000 post-share consolidation (or 1,100,000
pre-share consolidation) Series B Common Share Purchase Warrants
(the "Series B Warrants") subject to the previously disclosed
November 1, 2015 agreement were
exercised on November 23, 2015, which
will result in the issuance of 365,518 additional Common
Shares. After giving effect to the issuance of such shares,
there will be approximately 6.9 million Common Shares issued and
outstanding.
David A. Dodd, Chairman,
President and Chief Executive Officer of the Company explained,
"The holders of Series B Warrants who agreed on November 1, 2015 to exercise all of the
approximately 41,000 post-consolidation (or approximately 4.1
million pre-consolidation) Series B Warrants then held by them have
now exercised all of such Series B Warrants. Following our
recent share consolidation, there now remain outstanding
approximately 8,000 Series B Warrants held by a holder who was not
a party to the November 1
agreement. This holder has not exercised any of the Series B
Warrants issued to it in connection with our March 2015 offering. With the exercise of
the final Series B Warrants subject to the November 1 agreement, we believe that the
dilution of our Common Shares by the Series B Warrants is
substantially finished."
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women's health. For more
information, visit www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.